Furthermore, selective ERK inhibition induces tumor regression in MEK inhibitor-resistant models (67), raising the question of whether PARP inhibition could be similarly effective in either MEK or ERK-resistant tumors due to its proximity in the signaling pathway. The gene discussed is MAP2K7; the disease is neoplasm.